Abbott : Data Showcase Benefits Of Minimally Invasive Devices For People With Leaky Heart Valves

(RTTNews) - Abbott (ABT) announced data from late-breaking presentations showing the impact of its minimally invasive heart devices in treating mitral and tricuspid valve disease. Data include findings from the Triluminate pivotal trial that reinforce the safety and effectiveness of the TriClip transcatheter edge-to-edge repair or TEER system for patients with symptomatic, severe tricuspid regurgitation or TR despite optimal medical therapy. TriClip is an investigational device in the U.S.

The company also presented late-breaking data from the MitraClip EXPAND G4 real-world registry that highlights the device's benefits across a broad group of patients with mitral regurgitation or MR.

Leaky valves in people with MR and TR can reduce the amount of blood being pumped through the body and make the heart work harder than it should. As a result, MR and TR can lead to other cardiovascular issues as well as severely limit a person's quality of life. While historically surgery was often necessary to combat MR and TR, Abbott's minimally invasive portfolio of structural heart devices has allowed more people around the world to be effectively treated without the risk of surgical complications.

TriClip is approved for use in more than 50 countries, including in Europe and Canada, and is an investigational device in the U.S.

For More Such Health News, visit rttnews.com